The aquablation therapy market is projected to grow from USD 2,192.0 million in 2026 to USD 7,055.1 million by 2036, at a CAGR of 12.4%. Aquablation consoles will dominate with a 36.0% market share, while benign prostatic hyperplasia (bph) will lead the therapeutic applications segment with a 72.0% share.